Navigation Links
New Position Statement from The North American Menopause Society,Addresses Use of Local Estrogen for Treatment of Vaginal Atrophy in,Postmenopausal Women

CLEVELAND--(BUSINESS WIRE)--May 10, 2007 - An evaluation of the safety and effectiveness of local vaginal estrogen therapy for the treatment of vaginal atrophy, a frequent complaint of postmenopausal women, has just been released by The North American Menopause Society (NAMS). Entitled "The role of local vaginal estrogen for treatment of vaginal atrophy in postmenopausal women: 2007 position statement of The North American Menopause Society," the document was developed by an Editorial Board of five clinicians and researchers expert in this area of women's health, then approved by the NAMS Board of Trustees.

"Although hot flashes typically accompany the loss of ovarian estrogen production at menopause, they usually abate over time regardless of whether estrogen therapy is used," said Gloria A. Bachmann, MD, Associate Dean for Women's Health, Professor of Obstetrics and Gynecology and Professor of Medicine, UMDNJ, Robert Wood Johnson Medical School, New Brunswick, NJ, and Chair of the Editorial Board. "In contrast, vaginal symptoms (eg, vaginal dryness, vulvovaginal irritation and itching, and painful intercourse) are usually progressive and unlikely to resolve spontaneously. Left untreated, vaginal atrophy can result in years of discomfort, with a significant impact on quality of life. An estimated 10% to 40% of postmenopausal women have symptoms related to vaginal atrophy, yet only about 25% of symptomatic women seek medical help."

The new position statement represents the most authoritative state-of-the-science summary. Significant findings include:

-- Estrogen therapy, used either locally (ie, vaginally) or systemically (eg, orally, through the skin), is considered the therapeutic standard for moderate to severe vaginal atrophy.

-- Local vaginal delivery of estrogen is available in North America in government-approved therapies via cream, tablet, and ring--with fewer systemic effects than estrogen by topical, parenteral, or oral delivery.

-- Randomized controlled trials, although limited, have shown that low-dose, local vaginal estrogen delivery is effective and well tolerated for treating vaginal atrophy.

-- All the low-dose vaginal estrogen products approved in the United States for treatment of vaginal atrophy are equally effective at the doses recommended in labeling. Choice of therapy should be guided by clinical experience and patient preference.

-- Progestogen is generally not indicated when low-dose estrogen is used locally for vaginal atrophy.

-- Data are insignificant to recommend annual surveillance of the endometrium (lining of uterus) in asymptomatic women using vaginal estrogen.

-- Vaginal estrogen therapy should be continued for as long as symptoms that are distressing to the patient remain.

-- For women treated for non-hormone-dependent cancer, management of vaginal atrophy is similar to that for women without a cancer history.

-- For women with a history of hormone-dependent cancer, management recommendations are dependent upon each woman's preference in consultation with her oncologist.

The position statement is published in the May/June 2007 issue of the Society's official journal, Menopause. It has been designated a NAMS CME activity (print/online). A PDF of the paper, as well as a set of nine slides that summarize the paper's contents, are available without charge from the NAMS Web site (http://www.menopause.org/aboutmeno/consensus.htm).

NAMS is grateful to Novo Nordisk, Inc., for its educational grant that supported development of this statement.

The Mission of NAMS, a nonprofit scientific organization, is to promote the health and quality of life of women through an understanding of menopause. The Society's membership of 2,000 professionals representing a variety of disciplines--including clinical and basic science experts from medicine, nursing, pharmacy, a nthropology, sociology, psychology, and complementary/alternative medicine--makes NAMS uniquely qualified to serve as the definitive resource for health professionals and the public for accurate, unbiased information about menopause. (www.menopause.org)

Contact

McKinney Advertising & Public Relations
Judy Cerne, 216-621-5133
President & CEO
Fax: 216-621-1181
E-mail: jcerne@mckinneyad.com
or
The North American Menopause Society
Pamela P. Boggs, MBA, 440-442-7658
Director of Education & Development
Fax: 440-442-2660


'"/>




Related medicine technology :

1. Lupus Foundation of America Statement on Results for Clinical Study of CellCept Released by Aspreva Pharmaceutical Company
2. Obama Statement on Bush Veto of Stem Cell Bill
3. Statement by Philip Home Chairman of the RECORD Study Steering Committee and Professor of Diabetes Medicine at Newcastle University in England
4. West Nile Virus Screening and Diagnostics Technology Emerges In Step with North American Outbreak
5. Northfield Laboratories Reports Results of Pivotal Phase III Trauma Study
6. Northfield Laboratories Investor Update
7. Positive Aggrastat Results Featured in the Journal of the American College of Cardiology
8. Clinical Data From Nymox BPH Drug To Be Presented at American Urological Association Meeting
9. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
10. Sangamo BioSciences Announces Presentation of Phase 1 ZFP Therapeutic Data at American Diabetes Association Meeting
11. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that ... PCT (procalcitonin) assay as a dedicated testing solution for ... clearance, Roche is the first IVD company in the ... risk assessment and management. PCT is a ... in blood can aid clinicians in assessing the risk ...
(Date:6/23/2016)... June 23, 2016 Bracket , a leading ... next generation clinical outcomes platform, Bracket eCOA (SM) 6.0, ... June 26 – 30, 2016 in Philadelphia ... Clinical Outcome Assessment product of its kind to fully integrate ... Bracket eCOA 6.0 is a flexible platform for electronic ...
(Date:6/23/2016)... Revolutionary technology includes multi-speaker listening ... industry leaders in advanced audiology and hearing aid technology, ... ™, the world,s first internet connected hearing aid that ...      (Photo: http://photos.prnewswire.com/prnh/20160622/382240 ) , ... ,world firsts,: , TwinLink™ - the first ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... June 24, 2016 , ... ... skills and infrastructure. Most providers, however, are unsure how to move forward, given ... to define a path forward tailored to an organization’s specific needs. , ...
(Date:6/24/2016)... ... June 24, 2016 , ... Today, InhaleLabs.com (Inhale) offilially launched its ... by matching users with high quality water pipes within an ideal price range. The ... Inhale was founded by two brothers, Nick and Mike Hunter, who use medical cannabis ...
(Date:6/24/2016)... ... 24, 2016 , ... Dr. Seema Daulat, a native Texan and University of ... location as of July 13, 2016. , Dr. Daulat earned her Doctorate of Medicine ... regularly volunteered at the Agape Clinic serving Dallas’ underprivileged community. , Following medical school, ...
(Date:6/23/2016)... Los Angeles, CA (PRWEB) , ... June 23, 2016 , ... ... being conducted that may expose a possible link between head and neck cancer in ... individuals participating in the study were evaluated based on whether they had gum disease, ...
(Date:6/23/2016)... ... June 23, 2016 , ... The Mechille Wilson Agency, a Texas-based insurance ... and the surrounding region, is initiating a charity drive to assist a student to ... for a scholarship fund that will be presented to the chosen student to help ...
Breaking Medicine News(10 mins):